IRIDEX (NASDAQ:IRIX) Stock: Insider Shih-Yao David Lin Acquires 15,000 Shares

IRIDEX Corporation (NASDAQ:IRIX) major shareholder Shih-Yao David Lin purchased 15,000 shares of the company’s stock in a transaction that occurred on Friday, April 4th. The shares were acquired at an average cost of $0.89 per share, for a total transaction of $13,350.00. Following the completion of the transaction, the insider directly owned 28,834 shares of the company’s stock, valued at $25,662.26. This trade represents a 108.43% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.

IRIDEX Trading Up 2.2%

Shares of IRIDEX stock opened at $0.90 on Friday. IRIDEX Corporation has a 1 year low of $0.61 and a 1 year high of $1.65. The company has a market cap of $15.78 million, a P/E ratio of -4.49 and a beta of 0.67. The stock has a 50-day moving average price of $0.73 and a 200 day moving average price of $0.95.

IRIDEX (NASDAQ:IRIX) last released its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The business had revenue of $12.57 million during the quarter, compared to the consensus estimate of $13.59 million. On average, equities analysts forecast that IRIDEX Corporation will post -0.12 earnings per share for the current fiscal year.

Key Stories Impacting IRIDEX

Here are the key news stories impacting IRIDEX this week:

• Positive Sentiment: Lin reported another purchase of 10,000 IRIX shares at an average price of $1.05, worth $10,500. The transaction increased his direct holdings to 735,561 shares. IRIDEX major shareholder buys 10,000 shares
• Positive Sentiment: SEC disclosures show a sustained accumulation campaign by Lin, including purchases of 50,000 shares at $0.99, 40,114 shares at $1.00 and 80,000 shares at $1.00, along with numerous other transactions. Repeated buying by a major shareholder may signal confidence in IRIDEX’s longer-term prospects and can support momentum in a low-market-cap stock. IRIDEX major shareholder buys 50,000 shares
• Positive Sentiment: Several institutional investors also increased positions, including Perkins Capital Management, Thompson Davis, and Renaissance Technologies. Institutions own approximately 20.1% of IRIDEX’s shares, providing additional ownership support, though their disclosed positions remain relatively small in dollar terms.
• Neutral Sentiment: Trading in IRIX was temporarily halted under a Limit Up-Limit Down pause. The halt underscores unusually high volatility and the possibility of sharp price reversals when trading resumes.
• Neutral Sentiment: Analyst sentiment remains mixed: one analyst rates the stock Buy and another Sell, resulting in a consensus Hold rating. The reported consensus price target is $3.00, but the limited coverage reduces its reliability.
• Negative Sentiment: IRIDEX’s latest reported quarter remains a fundamental concern. The company posted a $0.07-per-share loss versus a $0.01 expected loss and revenue of $12.57 million versus the $13.59 million consensus estimate. Analysts expect a full-year loss of approximately $0.12 per share.

Institutional Investors Weigh In On IRIDEX

A number of large investors have recently bought and sold shares of the business. United Capital Financial Advisors LLC bought a new position in IRIDEX during the second quarter valued at about $41,000. Bank of New York Mellon Corp bought a new position in shares of IRIDEX in the 2nd quarter valued at approximately $29,000. Weber Capital Management LLC ADV acquired a new stake in IRIDEX in the 2nd quarter worth approximately $206,616. Diversify Advisory Services LLC bought a new stake in IRIDEX during the second quarter worth approximately $30,000. Finally, Renaissance Technologies LLC raised its position in shares of IRIDEX by 6.7% in the first quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after purchasing an additional 25,067 shares during the period. 20.10% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings raised shares of IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 2nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, IRIDEX has an average rating of “Hold” and a consensus target price of $3.00.

About IRIDEX

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.